GlassScriptPhysician profile
Michael Andrew Silao
NPI 1497706147
$7,103.44
in general payments reported to CMS, 2019-2025
40 companies · $791 in 2025
The $791 reported for 2025 was more than what 81% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $846 · 2020: $1,394 · 2021: $1,268 · 2022: $1,014 · 2023: $699 · 2024: $1,091 · 2025: $791.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,581.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,581.33 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $840.12 | 2019-2025 | Xifaxan, Trulance |
| Bayer Healthcare Pharmaceuticals INC. | $669.90 | 2021-2025 | |
| Novo Nordisk INC | $573.31 | 2019-2024 | Ozempic, Rybelsus |
| Boehringer Ingelheim Pharmaceuticals, INC. | $460.33 | 2020-2025 | Jardiance |
| Pfizer INC. | $454.49 | 2019-2023 | |
| Glaxosmithkline, LLC. | $430.59 | 2019-2024 | Trelegy Ellipta, Arexvy, Shingrix |
| Lilly USA, LLC | $382.50 | 2022-2025 | Jardiance, Zepbound, Mounjaro |
| Astrazeneca Pharmaceuticals LP | $340.98 | 2020-2022 | |
| Arbor Pharmaceuticals, INC. | $340.72 | 2019-2022 | |
| Gilead Sciences, INC. | $258.92 | 2019-2025 | |
| Amgen INC. | $243.17 | 2022-2025 | Repatha, Otezla, Krystexxa |
| Merck Sharp & Dohme LLC | $231.98 | 2019-2022 | |
| Inari Medical, INC. | $214.13 | 2024 | Ct Thrombectomy System Kit, Flowtriever Catheter, S |
| Avanir Pharmaceuticals, INC. | $160.22 | 2019-2021 | |
| Janssen Pharmaceuticals, INC | $154.01 | 2019-2021 |
Show all 40 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Silao listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.